Acer Therapeutics Inc.

When Zevra Therapeutics, then known as KemPharm, bought arimoclomol for peanuts with its acquisition of Orphazyme in 2022, it looked like a great bit of business and further confirmation has come wi

Zevra Therapeutics Inc. received the first-ever US Food and Drug Administration approval in Niemann-Pick disease type C (NPC) for Miplyffa (arimoclomol), but faces some complicating factors: co-admin

Zevra Therapeutics is hoping to hit the ground running with its Niemann-Pick disease type C (NPC) therapy arimoclomol in the autumn if it gets through an advisory committee with US regulators. The pa

Zevra Therapeutics is to acquire struggling Acer Therapeutics Inc. to expands its rare disease activities and add a commercial product for urea cycle disorders (UCDs). In a deal worth up to $91m, i